Other Videos From Series
AvaGen™ is the first and leading personalized genetic eye test that quantifies the risk of keratoconus or presence TGFBI corneal dystrophies by gene variants. AvaGen™ delivers a valuable tool for early and accurate decision-making that protects vision for patients and their families.
Avellino is a global leader in gene therapy and molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing.
The Company proudly launched AvaGen™ nationally in June 2021, providing eye care professionals in the US access to the first genetic test that provides them personalized genetic data to accurately quantify the genetic risk of keratoconus and the presence of TGFBI related corneal dystrophies. The test also helps ECPs understand the genetic risk of keratoconus in suspect and even asymptomatic patients to enable early sight-saving interventions and informed surgical decisions.